Jubilant Ingrevia Ltd
Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with our customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards.
Jubilant Ingrevia’s portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis. [1]
- Market Cap ₹ 10,418 Cr.
- Current Price ₹ 653
- High / Low ₹ 726 / 406
- Stock P/E 74.2
- Book Value ₹ 141
- Dividend Yield 0.77 %
- ROCE 10.3 %
- ROE 7.37 %
- Face Value ₹ 1.00
Pros
- Company has been maintaining a healthy dividend payout of 32.7%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|
0 | 669 | 4,860 | 4,560 | 3,987 | 3,926 | |
0 | 572 | 4,039 | 4,064 | 3,584 | 3,549 | |
Operating Profit | -0 | 97 | 821 | 496 | 403 | 377 |
OPM % | 14% | 17% | 11% | 10% | 10% | |
0 | -10 | 21 | 30 | 36 | 35 | |
Interest | 0 | 9 | 46 | 38 | 66 | 68 |
Depreciation | 0 | 21 | 120 | 120 | 133 | 138 |
Profit before tax | -0 | 56 | 675 | 368 | 239 | 207 |
Tax % | 0% | 31% | 33% | 31% | 32% | |
-0 | 39 | 452 | 253 | 162 | 140 | |
EPS in Rs | -3.40 | 2.42 | 28.39 | 15.91 | 10.20 | 8.81 |
Dividend Payout % | 0% | 14% | 18% | 31% | 49% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 81% |
TTM: | -11% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 51% |
TTM: | -39% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -3% |
1 Year: | 28% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 14% |
Last Year: | 7% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Equity Capital | 0 | 16 | 16 | 16 | 16 |
Reserves | -0 | 1,560 | 1,967 | 2,143 | 2,231 |
0 | 782 | 469 | 645 | 870 | |
0 | 882 | 1,200 | 1,255 | 1,224 | |
Total Liabilities | 0 | 3,240 | 3,652 | 4,058 | 4,340 |
0 | 1,727 | 1,728 | 1,775 | 2,292 | |
CWIP | 0 | 65 | 167 | 477 | 180 |
Investments | 0 | 135 | 139 | 172 | 297 |
0 | 1,313 | 1,619 | 1,635 | 1,571 | |
Total Assets | 0 | 3,240 | 3,652 | 4,058 | 4,340 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
0 | 104 | 587 | 446 | 394 | |
0 | 32 | -221 | -475 | -464 | |
0 | -70 | -410 | 33 | 64 | |
Net Cash Flow | 0 | 66 | -44 | 3 | -6 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Debtor Days | 262 | 44 | 40 | 52 | |
Inventory Days | 490 | 97 | 127 | 132 | |
Days Payable | 649 | 101 | 117 | 129 | |
Cash Conversion Cycle | 103 | 40 | 50 | 55 | |
Working Capital Days | 230 | 42 | 45 | 53 | |
ROCE % | 7% | 30% | 16% | 10% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 23h
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 13 Aug
- Announcement under Regulation 30 (LODR)-Credit Rating 12 Aug
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 Aug - Announcement under Regulation 30 (LODR) for Newspaper Publication for Notice of 5th Annual General Meeting
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
9 Aug - Newspaper advertisement titled ''Notice of 5th Annual General Meeting, E-Voting, Record date and Final Dividend Intimation''
Annual reports
Concalls
-
Jul 2024Transcript PPT
-
May 2024Transcript PPT REC
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT REC
-
Jul 2023Transcript PPT REC
-
Jul 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
May 2023TranscriptNotesPPT
-
Feb 2023TranscriptPPT
-
Feb 2023TranscriptPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022TranscriptPPT
-
Mar 2022TranscriptNotesPPT
-
Mar 2022TranscriptNotesPPT
-
Feb 2022TranscriptPPT
-
Oct 2021TranscriptNotesPPT
-
Sep 2021TranscriptNotesPPT
-
Aug 2021TranscriptPPT
-
Jun 2021Transcript PPT
-
May 2021TranscriptPPT
Leadership[1]
# 40+ years of legacy in Chemicals space, started in 1978
# Global player in Pyridine + Beta, Vitamin B3 and Acetic Anhydride.
# Serves 15 of the top 20 Global Pharma & 7 of the top 10 Global Agrochemical companies.
# Leading Low-Cost provider